Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2000 Jul;53(7):487–496. doi: 10.1136/jcp.53.7.487

Lipoprotein (a) and stroke

H Milionis 1, A Winder 1, D Mikhailidis 1
PMCID: PMC1731226  PMID: 10961170

Abstract

Strokes are one of the most common causes of mortality and long term severe disability. There is evidence that lipoprotein (a) (Lp(a)) is a predictor of many forms of vascular disease, including premature coronary artery disease. Several studies have also evaluated the association between Lp(a) and ischaemic (thrombotic) stroke. Several cross sectional (and a few prospective) studies provide contradictory findings regarding Lp(a) as a predictor of ischaemic stroke. Several factors might contribute to the existing confusion—for example, small sample sizes, different ethnic groups, the influence of oestrogens in women participating in the studies, plasma storage before Lp(a) determination, statistical errors, and selection bias. This review focuses on the Lp(a) related mechanisms that might contribute to the pathogenesis of ischaemic stroke. The association between Lp(a) and other cardiovascular risk factors is discussed. Therapeutic interventions that can lower the circulating concentrations of Lp(a) and thus possibly reduce the risk of stroke are also considered.

Key Words: atherothrombosis • fibrinogen • homocysteine • lipids • lipoprotein a • stroke

Full Text

The Full Text of this article is available as a PDF (165.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfthan G., Pekkanen J., Jauhiainen M., Pitkäniemi J., Karvonen M., Tuomilehto J., Salonen J. T., Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994 Mar;106(1):9–19. doi: 10.1016/0021-9150(94)90078-7. [DOI] [PubMed] [Google Scholar]
  2. Asanuma Y., Kawai S., Aoshima H., Kaburaki J., Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum. 1999 Mar;42(3):443–447. doi: 10.1002/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  3. Aznar J., Estellés A., Bretó M., España F. Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thromb Res. 1993 Dec 1;72(5):459–465. doi: 10.1016/0049-3848(93)90247-l. [DOI] [PubMed] [Google Scholar]
  4. Bartens W., Rader D. J., Talley G., Brewer H. B., Jr Lipoprotein (a) in patients with hyperlipidaemia. Eur J Clin Invest. 1995 Sep;25(9):647–653. doi: 10.1111/j.1365-2362.1995.tb01980.x. [DOI] [PubMed] [Google Scholar]
  5. Beamer N. B., Coull B. M., Clark W. M., Briley D. P., Wynn M., Sexton G. Persistent inflammatory response in stroke survivors. Neurology. 1998 Jun;50(6):1722–1728. doi: 10.1212/wnl.50.6.1722. [DOI] [PubMed] [Google Scholar]
  6. Beisiegel U., Niendorf A., Wolf K., Reblin T., Rath M. Lipoprotein(a) in the arterial wall. Eur Heart J. 1990 Aug;11 (Suppl E):174–183. doi: 10.1093/eurheartj/11.suppl_e.174. [DOI] [PubMed] [Google Scholar]
  7. Boerwinkle E., Leffert C. C., Lin J., Lackner C., Chiesa G., Hobbs H. H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992 Jul;90(1):52–60. doi: 10.1172/JCI115855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boman L., Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes Surg. 1997 Apr;7(2):125–127. doi: 10.1381/096089297765556006. [DOI] [PubMed] [Google Scholar]
  9. Byrne C. D., Lawn R. M. Studies on the structure and function of the apolipoprotein(a) gene. Clin Genet. 1994 Jul;46(1 Spec No):34–41. doi: 10.1111/j.1399-0004.1994.tb04199.x. [DOI] [PubMed] [Google Scholar]
  10. Carlson L. A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989 Oct;226(4):271–276. doi: 10.1111/j.1365-2796.1989.tb01393.x. [DOI] [PubMed] [Google Scholar]
  11. Catalano M., Perilli E., Carzaniga G., Colombo F., Carotta M., Andreoni S. Lp(a) in hypertensive patients. J Hum Hypertens. 1998 Feb;12(2):83–89. doi: 10.1038/sj.jhh.1000540. [DOI] [PubMed] [Google Scholar]
  12. Chapman M. J., Huby T., Nigon F., Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis. 1994 Oct;110 (Suppl):S69–S75. doi: 10.1016/0021-9150(94)05385-v. [DOI] [PubMed] [Google Scholar]
  13. Cheng S. W., Ting A. C., Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg. 1997 Jul;14(1):17–23. doi: 10.1016/s1078-5884(97)80220-1. [DOI] [PubMed] [Google Scholar]
  14. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  15. Cohen A., Tzourio C., Bertrand B., Chauvel C., Bousser M. G., Amarenco P. Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. Circulation. 1997 Dec 2;96(11):3838–3841. doi: 10.1161/01.cir.96.11.3838. [DOI] [PubMed] [Google Scholar]
  16. Cortinovis A., Crippa A., Crippa M. Emoreologia e fibrinogenemia: due parametri indipendenti nella valutazione del danno vascolare cerebrale. Minerva Med. 1995 Dec;86(12):511–518. [PubMed] [Google Scholar]
  17. Couderc R., Mahieux F., Bailleul S., Fenelon G., Mary R., Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke. 1993 May;24(5):661–664. doi: 10.1161/01.str.24.5.661. [DOI] [PubMed] [Google Scholar]
  18. Craig W. Y., Ledue T. B. Lipoprotein(a) and the acute phase response. Clin Chim Acta. 1992 Sep 30;210(3):231–232. doi: 10.1016/0009-8981(92)90209-9. [DOI] [PubMed] [Google Scholar]
  19. Cremer P., Nagel D., Labrot B., Mann H., Muche R., Elster H., Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994 Jul;24(7):444–453. doi: 10.1111/j.1365-2362.1994.tb02373.x. [DOI] [PubMed] [Google Scholar]
  20. Cremer P., Nagel D., Seidel D., van de Loo J. C., Kienast J. Considerations about plasma fibrinogen concentration and the cardiovascular risk: combined evidence from the GRIPS and ECAT studies. Goettingen Risk Incidence and Prevalence Study. European Concerted Action on Thrombosis and Disabilities. Am J Cardiol. 1996 Aug 1;78(3):380–381. [PubMed] [Google Scholar]
  21. Crook D., Sidhu M., Seed M., O'Donnell M., Stevenson J. C. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 1992 Jan;92(1):41–47. doi: 10.1016/0021-9150(92)90008-5. [DOI] [PubMed] [Google Scholar]
  22. D'Erasmo E., Acca M., Celi F. S., Medici F., Palmerini T., Pisani D. Plasma fibrinogen and platelet count in stroke. J Med. 1993;24(2-3):185–191. [PubMed] [Google Scholar]
  23. Dahlén G. H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994 Aug;108(2):111–126. doi: 10.1016/0021-9150(94)90106-6. [DOI] [PubMed] [Google Scholar]
  24. Delanty N., Vaughan C. J. Vascular effects of statins in stroke. Stroke. 1997 Nov;28(11):2315–2320. doi: 10.1161/01.str.28.11.2315. [DOI] [PubMed] [Google Scholar]
  25. Di Mascio R., Marchioli R., Vitullo F., Di Pasquale A., Cavasinni L., Tognoni G. Serum cholesterol and risk of ischemic stroke: results of a case-control study. On behalf of PROGETTO 3A Investigators. Prev Med. 1995 Mar;24(2):128–133. doi: 10.1006/pmed.1995.1025. [DOI] [PubMed] [Google Scholar]
  26. Durand P., Lussier-Cacan S., Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997 Nov;11(13):1157–1168. [PubMed] [Google Scholar]
  27. Elisaf M., Bairaktari E., Nicolaides C., Fountzilas G., Tzallas C., Siamopoulos K., Tsolas O., Pavlidis N. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res. 1996 Sep-Oct;16(5A):2725–2728. [PubMed] [Google Scholar]
  28. Elkeles R. S., Diamond J. R., Poulter C., Dhanjil S., Nicolaides A. N., Mahmood S., Richmond W., Mather H., Sharp P., Feher M. D. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998 Apr;21(4):641–648. doi: 10.2337/diacare.21.4.641. [DOI] [PubMed] [Google Scholar]
  29. Emond M. J., Zareba W. Prognostic value of cholesterol in women of different ages. J Womens Health. 1997 Jun;6(3):295–307. doi: 10.1089/jwh.1997.6.295. [DOI] [PubMed] [Google Scholar]
  30. Engler H., Riesen W. F. Effect of thyroid function on concentrations of lipoprotein(a) Clin Chem. 1993 Dec;39(12):2466–2469. [PubMed] [Google Scholar]
  31. Farish E., Spowart K., Barnes J. F., Fletcher C. D., Calder A., Brown A., Hart D. M. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis. 1996 Sep 27;126(1):77–84. doi: 10.1016/0021-9150(96)05895-9. [DOI] [PubMed] [Google Scholar]
  32. Fath-Ordoubadi F., Pagano D., Marinho N. V., Keogh B. E., Bonser R. S., Camici P. G. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction. Am J Cardiol. 1998 Jul 1;82(1):26–31. doi: 10.1016/s0002-9149(98)00241-0. [DOI] [PubMed] [Google Scholar]
  33. Feely J., Barry M., Keeling P. W., Weir D. G., Cooke T. Lipoprotein(a) in cirrhosis. BMJ. 1992 Feb 29;304(6826):545–546. doi: 10.1136/bmj.304.6826.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Fonte G., Bo M., Poli L., Fiandra U., Fabris F. Stroke ischemico e attacchi ischemici transitori: studio caso-controllo sui fattori di rischio in pazienti anziani ospedalizzati. Recenti Prog Med. 1993 Apr;84(4):254–262. [PubMed] [Google Scholar]
  35. Freeman D. J., Griffin B. A., Murray E., Lindsay G. M., Gaffney D., Packard C. J., Shepherd J. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest. 1993 Oct;23(10):630–640. doi: 10.1111/j.1365-2362.1993.tb00724.x. [DOI] [PubMed] [Google Scholar]
  36. Fukujima M. M., Martinez T. L., Pinto L. E., Auriemo C. do R., de Andrade L. A. Fibrinogênio como fator de risco independente de doença vascular cerebral. Arq Neuropsiquiatr. 1997 Dec;55(4):737–740. doi: 10.1590/s0004-282x1997000500009. [DOI] [PubMed] [Google Scholar]
  37. Gatchev O., Råstam L., Lindberg G., Gullberg B., Eklund G. A., Isacsson S. O. Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women. Ann Epidemiol. 1993 Jul;3(4):403–409. doi: 10.1016/1047-2797(93)90068-f. [DOI] [PubMed] [Google Scholar]
  38. Gaw A., Boerwinkle E., Cohen J. C., Hobbs H. H. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus. J Clin Invest. 1994 Jun;93(6):2526–2534. doi: 10.1172/JCI117263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Gaw A., Brown E. A., Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1870–1876. doi: 10.1161/01.atv.18.12.1870. [DOI] [PubMed] [Google Scholar]
  40. Gazzaruso C., Buscaglia P., Garzaniti A., Falcone C., Mariotti S., Savino S., Bonetti G., Finardi G., Geroldi D. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens. 1997 Mar;15(3):227–235. doi: 10.1097/00004872-199715030-00003. [DOI] [PubMed] [Google Scholar]
  41. Glader C. A., Stegmayr B., Boman J., Stenlund H., Weinehall L., Hallmans G., Dahlén G. H. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke. 1999 Oct;30(10):2013–2018. doi: 10.1161/01.str.30.10.2013. [DOI] [PubMed] [Google Scholar]
  42. Gordon T., Kannel W. B., Castelli W. P., Dawber T. R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981 Aug;141(9):1128–1131. [PubMed] [Google Scholar]
  43. Hachinski V., Graffagnino C., Beaudry M., Bernier G., Buck C., Donner A., Spence J. D., Doig G., Wolfe B. M. Lipids and stroke: a paradox resolved. Arch Neurol. 1996 Apr;53(4):303–308. doi: 10.1001/archneur.1996.00550040031011. [DOI] [PubMed] [Google Scholar]
  44. Harpel P. C., Chang V. T., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10193–10197. doi: 10.1073/pnas.89.21.10193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Heinrich J., Sandkamp M., Kokott R., Schulte H., Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991 Nov;37(11):1950–1954. [PubMed] [Google Scholar]
  46. Heinzlef O., Cohen A., Amarenco P. An update on aortic causes of ischemic stroke. Curr Opin Neurol. 1997 Feb;10(1):64–72. doi: 10.1097/00019052-199702000-00013. [DOI] [PubMed] [Google Scholar]
  47. Hobbs H. H., White A. L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999 Jun;10(3):225–236. doi: 10.1097/00041433-199906000-00005. [DOI] [PubMed] [Google Scholar]
  48. Hopkins P. N., Wu L. L., Hunt S. C., James B. C., Vincent G. M., Williams R. R. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2783–2792. doi: 10.1161/01.atv.17.11.2783. [DOI] [PubMed] [Google Scholar]
  49. Hornstra G., van Houwelingen A. C., Kester A. D., Sundram K. A palm oil-enriched diet lowers serum lipoprotein(a) in normocholesterolemic volunteers. Atherosclerosis. 1991 Sep;90(1):91–93. doi: 10.1016/0021-9150(91)90247-z. [DOI] [PubMed] [Google Scholar]
  50. Huby T., Chapman J., Thillet J. Pathophysiological implication of the structural domains of lipoprotein(a). Atherosclerosis. 1997 Aug;133(1):1–6. doi: 10.1016/s0021-9150(97)00111-1. [DOI] [PubMed] [Google Scholar]
  51. Hunninghake D. B., Stein E. A., Mellies M. J. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol. 1993 Jun;33(6):574–580. doi: 10.1002/j.1552-4604.1993.tb04706.x. [DOI] [PubMed] [Google Scholar]
  52. Ichinose A., Suzuki K., Saito T. Apolipoprotein(a) and thrombosis: molecular and genetic bases of hyper-lipoprotein(a)-emia. Semin Thromb Hemost. 1998;24(3):237–243. doi: 10.1055/s-2007-995848. [DOI] [PubMed] [Google Scholar]
  53. Ikeo K., Takahashi K., Gojobori T. Different evolutionary histories of kringle and protease domains in serine proteases: a typical example of domain evolution. J Mol Evol. 1995 Mar;40(3):331–336. doi: 10.1007/BF00163238. [DOI] [PubMed] [Google Scholar]
  54. Iribarren C., Jacobs D. R., Sadler M., Claxton A. J., Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke. 1996 Nov;27(11):1993–1998. doi: 10.1161/01.str.27.11.1993. [DOI] [PubMed] [Google Scholar]
  55. Islam S., Gutin B., Smith C., Treiber F., Kamboh M. I. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb. 1994 Oct;14(10):1609–1616. doi: 10.1161/01.atv.14.10.1609. [DOI] [PubMed] [Google Scholar]
  56. Iso H., Jacobs D. R., Jr, Wentworth D., Neaton J. D., Cohen J. D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989 Apr 6;320(14):904–910. doi: 10.1056/NEJM198904063201405. [DOI] [PubMed] [Google Scholar]
  57. Jacobs D. R. The relationship between cholesterol and stroke. Health Rep. 1994;6(1):87–93. [PubMed] [Google Scholar]
  58. Jürgens G., Költringer P. Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries. Chem Phys Lipids. 1994 Jan;67-68:429–434. doi: 10.1016/0009-3084(94)90166-x. [DOI] [PubMed] [Google Scholar]
  59. Jürgens G., Költringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987 Mar;37(3):513–515. doi: 10.1212/wnl.37.3.513. [DOI] [PubMed] [Google Scholar]
  60. Jürgens G., Taddei-Peters W. C., Költringer P., Petek W., Chen Q., Greilberger J., Macomber P. F., Butman B. T., Stead A. G., Ransom J. H. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 1995 Oct;26(10):1841–1848. doi: 10.1161/01.str.26.10.1841. [DOI] [PubMed] [Google Scholar]
  61. Kario K., Matsuo T., Kobayashi H., Asada R., Matsuo M. 'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):734–741. doi: 10.1161/01.atv.16.6.734. [DOI] [PubMed] [Google Scholar]
  62. Kawamoto A., Shimada K., Matsubayashi K., Nishinaga M., Kimura S., Ozawa T. Factors associated with silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic elderly hypertensive patients. Clin Exp Pharmacol Physiol. 1991 Sep;18(9):605–610. doi: 10.1111/j.1440-1681.1991.tb01633.x. [DOI] [PubMed] [Google Scholar]
  63. Koenig W. Recent progress in the clinical aspects of fibrinogen. Eur Heart J. 1995 Mar;16 (Suppl A):54–59. doi: 10.1093/eurheartj/16.suppl_a.54. [DOI] [PubMed] [Google Scholar]
  64. Konemori G. Lipoprotein(a) and other risk factors for cerebral infarction. Hiroshima J Med Sci. 1995 Sep;44(3):65–77. [PubMed] [Google Scholar]
  65. Korn-Lubetzki I., Kleinman Y., Eliashiv S., Eliakim M. Correlation between serum lipids and stroke in an Israeli population. Neurol Res. 1992;14(2 Suppl):78–80. doi: 10.1080/01616412.1992.11740016. [DOI] [PubMed] [Google Scholar]
  66. Kostner G. M., Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J. 1990 Aug;11 (Suppl E):184–189. doi: 10.1093/eurheartj/11.suppl_e.184. [DOI] [PubMed] [Google Scholar]
  67. Kostner G. M., Gavish D., Leopold B., Bolzano K., Weintraub M. S., Breslow J. L. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989 Nov;80(5):1313–1319. doi: 10.1161/01.cir.80.5.1313. [DOI] [PubMed] [Google Scholar]
  68. Kronenberg F., König P., Neyer U., Auinger M., Pribasnig A., Lang U., Reitinger J., Pinter G., Utermann G., Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995 Jul;6(1):110–120. doi: 10.1681/ASN.V61110. [DOI] [PubMed] [Google Scholar]
  69. Kronenberg F., Steinmetz A., Kostner G. M., Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33(6):495–543. doi: 10.3109/10408369609080056. [DOI] [PubMed] [Google Scholar]
  70. Kronenberg F., Steinmetz A., Kostner G. M., Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33(6):495–543. doi: 10.3109/10408369609080056. [DOI] [PubMed] [Google Scholar]
  71. Kung A. W., Pang R. W., Lauder I., Lam K. S., Janus E. D. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem. 1995 Feb;41(2):226–231. [PubMed] [Google Scholar]
  72. Landray M. J., Sagar G., Muskin J., Murray S., Holder R. L., Lip G. Y. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM. 1998 May;91(5):345–351. doi: 10.1093/qjmed/91.5.345. [DOI] [PubMed] [Google Scholar]
  73. Lindenstrøm E., Boysen G., Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ. 1994 Jul 2;309(6946):11–15. doi: 10.1136/bmj.309.6946.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Lindgren A., Nilsson-Ehle P., Norrving B., Johansson B. B. Plasma lipids and lipoproteins in subtypes of stroke. Acta Neurol Scand. 1992 Dec;86(6):572–578. doi: 10.1111/j.1600-0404.1992.tb05489.x. [DOI] [PubMed] [Google Scholar]
  75. Maher V. M., Brown B. G., Marcovina S. M., Hillger L. A., Zhao X. Q., Albers J. J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995 Dec 13;274(22):1771–1774. [PubMed] [Google Scholar]
  76. Marcovina S. M., Albers J. J., Jacobs D. R., Jr, Perkins L. L., Lewis C. E., Howard B. V., Savage P. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study. Arterioscler Thromb. 1993 Jul;13(7):1037–1045. doi: 10.1161/01.atv.13.7.1037. [DOI] [PubMed] [Google Scholar]
  77. Marcovina S. M., Hobbs H. H., Albers J. J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996 Mar;42(3):436–439. [PubMed] [Google Scholar]
  78. Margaglione M., DiMinno G., Grandone E., Celentano E., Vecchione G., Cappucci G., Grilli M., Mancini F. P., Postiglione A., Panico S. Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):120–128. doi: 10.1161/01.atv.16.1.120. [DOI] [PubMed] [Google Scholar]
  79. Mathur S., Barradas M. A., Mikhailidis D. P., Dandona P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diabetes Res. 1990 Jul;14(3):133–138. [PubMed] [Google Scholar]
  80. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  81. Meade T. W., Vickers M. V., Thompson S. G., Stirling Y., Haines A. P., Miller G. J. Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 1985 Feb 9;290(6466):428–432. doi: 10.1136/bmj.290.6466.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Menotti A., Blackburn H., Kromhout D., Nissinen A., Karvonen M., Aravanis C., Dontas A., Fidanza F., Giampaoli S. The inverse relation of average population blood pressure and stroke mortality rates in the seven countries study: a paradox. Eur J Epidemiol. 1997 Jun;13(4):379–386. doi: 10.1023/a:1007326624702. [DOI] [PubMed] [Google Scholar]
  83. Mikhailidis D. P., Barradas M. A., Maris A., Jeremy J. Y., Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985 Oct;38(10):1166–1171. doi: 10.1136/jcp.38.10.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Mikhailidis D. P., Ganotakis E. S., Spyropoulos K. A., Jagroop I. A., Byrne D. J., Winder A. F. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol. 1998 Dec;17(4):225–233. [PubMed] [Google Scholar]
  85. Milionis H. J., Elisaf M. S., Tselepis A., Bairaktari E., Karabina S. A., Siamopoulos K. C. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis. 1999 Jun;33(6):1100–1106. doi: 10.1016/S0272-6386(99)70147-2. [DOI] [PubMed] [Google Scholar]
  86. Nagayama M., Shinohara Y., Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke. 1994 Jan;25(1):74–78. doi: 10.1161/01.str.25.1.74. [DOI] [PubMed] [Google Scholar]
  87. Nair D. R., Papadakis J. A., Jagroop I. A., Mikhailidis D. P., Winder A. F. Statins and fibrinogen. Lancet. 1998 May 9;351(9113):1430–1432. doi: 10.1016/s0140-6736(98)26019-3. [DOI] [PubMed] [Google Scholar]
  88. Neaton J. D., Blackburn H., Jacobs D., Kuller L., Lee D. J., Sherwin R., Shih J., Stamler J., Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jul;152(7):1490–1500. [PubMed] [Google Scholar]
  89. Nishio E., Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol. 1997 Sep;122(2):269–274. doi: 10.1038/sj.bjp.0701391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Ozawa H., Aono H., Saito I., Ikebe T. [Atherosclerosis and clinical examination: epidemiology of stroke and ischemic heart disease]. Rinsho Byori. 1996 Nov;44(11):1015–1026. [PubMed] [Google Scholar]
  91. Palmer A., Bulpitt C., Beevers G., Coles E., Fletcher A., Ledingham J., Petrie J., Webster J., Dollery C. Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients. J Hum Hypertens. 1995 Aug;9(8):695–697. [PubMed] [Google Scholar]
  92. Palomäki H., Kaste M., Raininko R., Salonen O., Juvela S., Sarna S. Risk factors for cervical atherosclerosis in patients with transient ischemic attack or minor ischemic stroke. Stroke. 1993 Jul;24(7):970–975. doi: 10.1161/01.str.24.7.970. [DOI] [PubMed] [Google Scholar]
  93. Pandolfi C., Pellegrini L., Dedè A., Lo Vecchio M., Mercantini F. Lipoproteina(a), parametri del metabolismo lipidico e dell'emostasi in pazienti obesi. Minerva Endocrinol. 1997 Mar;22(1):13–17. [PubMed] [Google Scholar]
  94. Papadakis J. A., Ganotakis E. S., Jagroop I. A., Mikhailidis D. P., Winder A. F. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens. 1999 Jul;12(7):673–681. doi: 10.1016/s0895-7061(99)00049-7. [DOI] [PubMed] [Google Scholar]
  95. Papadakis J. A., Mikhailidis D. P., Winder A. F. Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res. 1998 Nov;40(2):265–271. doi: 10.1016/s0008-6363(98)00222-3. [DOI] [PubMed] [Google Scholar]
  96. Peng D. Q., Zhao S. P., Wang J. L. Lipoprotein (a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk. 1999 Feb;6(1):1–6. doi: 10.1177/204748739900600101. [DOI] [PubMed] [Google Scholar]
  97. Peynet J., Beaudeux J. L., Woimant F., Flourié F., Giraudeaux V., Vicaut E., Launay J. M. Apolipoprotein(a) size polymorphism in young adults with ischemic stroke. Atherosclerosis. 1999 Jan;142(1):233–239. doi: 10.1016/s0021-9150(98)00232-9. [DOI] [PubMed] [Google Scholar]
  98. Postiglione A., Napoli C. Hyperlipidaemia and atherosclerotic cerebrovascular disease. Curr Opin Lipidol. 1995 Aug;6(4):236–242. doi: 10.1097/00041433-199508000-00008. [DOI] [PubMed] [Google Scholar]
  99. Postiglione A., Rubba P., De Simone B., Patti L., Cicerano U., Mancini M. Carotid atherosclerosis in familial hypercholesterolemia. Stroke. 1985 Jul-Aug;16(4):658–661. doi: 10.1161/01.str.16.4.658. [DOI] [PubMed] [Google Scholar]
  100. Puddey I. B. Low serum cholesterol and the risk of cerebral haemorrhage. Atherosclerosis. 1996 Jan 5;119(1):1–6. doi: 10.1016/0021-9150(95)05634-3. [DOI] [PubMed] [Google Scholar]
  101. Rastenyte D., Tuomilehto J., Domarkiene S., Cepaitis Z., Reklaitiene R. Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20-year prospective study. Stroke. 1996 Apr;27(4):672–676. doi: 10.1161/01.str.27.4.672. [DOI] [PubMed] [Google Scholar]
  102. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H. J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 Sep-Oct;9(5):579–592. doi: 10.1161/01.atv.9.5.579. [DOI] [PubMed] [Google Scholar]
  103. Reed D. M. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol. 1990 Apr;131(4):579–588. doi: 10.1093/oxfordjournals.aje.a115542. [DOI] [PubMed] [Google Scholar]
  104. Ridker P. M., Stampfer M. J., Hennekens C. H. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995 Apr 26;273(16):1269–1273. [PubMed] [Google Scholar]
  105. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410–418. doi: 10.1056/NEJM199908053410604. [DOI] [PubMed] [Google Scholar]
  106. Ryu J. E., Howard G., Craven T. E., Bond M. G., Hagaman A. P., Crouse J. R., 3rd Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke. 1992 Jun;23(6):823–828. doi: 10.1161/01.str.23.6.823. [DOI] [PubMed] [Google Scholar]
  107. Sacco R. L., Roberts J. K., Jacobs B. S. Homocysteine as a risk factor for ischemic stroke: an epidemiological story in evolution. Neuroepidemiology. 1998;17(4):167–173. doi: 10.1159/000026169. [DOI] [PubMed] [Google Scholar]
  108. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  109. Sandholzer C., Saha N., Kark J. D., Rees A., Jaross W., Dieplinger H., Hoppichler F., Boerwinkle E., Utermann G. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992 Oct;12(10):1214–1226. doi: 10.1161/01.atv.12.10.1214. [DOI] [PubMed] [Google Scholar]
  110. Schmidt E. B., Klausen I. C., Kristensen S. D., Lervang H. H., Faergeman O., Dyerberg J. The effect of n-3 polyunsaturated fatty acids on Lp(a). Clin Chim Acta. 1991 May 15;198(3):271–277. doi: 10.1016/0009-8981(91)90362-g. [DOI] [PubMed] [Google Scholar]
  111. Schreiner P. J., Chambless L. E., Brown S. A., Watson R. L., Toole J., Heiss G. Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1994 Sep;4(5):351–359. doi: 10.1016/1047-2797(94)90068-x. [DOI] [PubMed] [Google Scholar]
  112. Siamopoulos K. C., Elisaf M. S., Bairaktari H. T., Pappas M. B., Sferopoulos G. D., Nikolakakis N. G. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int. 1995 Oct-Dec;15(8):342–347. [PubMed] [Google Scholar]
  113. Slunga L., Asplund K., Johnson O., Dahlén G. H. Lipoprotein (a) in a randomly selected 25-64 year old population: the Northern Sweden Monica Study. J Clin Epidemiol. 1993 Jul;46(7):617–624. doi: 10.1016/0895-4356(93)90034-x. [DOI] [PubMed] [Google Scholar]
  114. Smith E. B., Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis. 1990 Oct;84(2-3):173–181. doi: 10.1016/0021-9150(90)90088-z. [DOI] [PubMed] [Google Scholar]
  115. Spinler S. A., Cziraky M. J. Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother. 1994 Mar;28(3):343–351. doi: 10.1177/106002809402800310. [DOI] [PubMed] [Google Scholar]
  116. Stein J. H., Rosenson R. S. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 1997 Jun 9;157(11):1170–1176. [PubMed] [Google Scholar]
  117. Stenvinkel P., Berglund L., Heimbürger O., Pettersson E., Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 1993 Nov;44(5):1116–1123. doi: 10.1038/ki.1993.357. [DOI] [PubMed] [Google Scholar]
  118. Suzuki K., Kuriyama M., Saito T., Ichinose A. Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region. J Clin Invest. 1997 Mar 15;99(6):1361–1366. doi: 10.1172/JCI119295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Tabas I., Li Y., Brocia R. W., Xu S. W., Swenson T. L., Williams K. J. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem. 1993 Sep 25;268(27):20419–20432. [PubMed] [Google Scholar]
  120. Taskinen M. R., Puolakka J., Pyörälä T., Luotola H., Bjärn M., Käriänen J., Lahdenperä S., Ehnholm C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1215–1221. doi: 10.1161/01.atv.16.10.1215. [DOI] [PubMed] [Google Scholar]
  121. Thompson S. G., Kienast J., Pyke S. D., Haverkate F., van de Loo J. C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 Mar 9;332(10):635–641. doi: 10.1056/NEJM199503093321003. [DOI] [PubMed] [Google Scholar]
  122. Vaverková H., Novotný D., Ficker L., Vlachová I., Chudácková J. Lipoprotein (a): genetický rizikový faktor predcasné ischemické cévní mozkové príhody. Vnitr Lek. 1993 Oct;39(10):979–987. [PubMed] [Google Scholar]
  123. Vila N., Deulofeu R., Chamorro A., Piera C. Concentraciones plasmáticas de homocisteína en pacientes con infarto cerebral isquémico. Med Clin (Barc) 1998 May 9;110(16):605–608. [PubMed] [Google Scholar]
  124. Watts G. F., Mazurkiewicz J. C., Tonge K., Nelson V., Warburton F. G., Slavin B. M. Lipoprotein(a) as a determinant of the severity of angiographically defined carotid atherosclerosis. QJM. 1995 May;88(5):321–326. [PubMed] [Google Scholar]
  125. Weber G., Alessandrini C., Centi L., Gerli R., Novelli M. T., Petrelli L., Resi L., Salvi M., Tanganelli P. Delayed development of intimal lesions in cerebral arteries of spontaneously hypertensive rats subjected to a short-term atherogenic diet (TEM observations). Appl Pathol. 1986;4(4):233–236. [PubMed] [Google Scholar]
  126. Weber G., Fabbrini P., Resi L., Sforza V., Tanganelli P., Vesselinovitch D., Wissler R. W. An ultrastructural comparison of diet-induced atherosclerosis of arteries supplying the central nervous system in cynomolgus and rhesus monkeys. Appl Pathol. 1983;1(3):121–138. [PubMed] [Google Scholar]
  127. Wild S. H., Fortmann S. P., Marcovina S. M. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997 Feb;17(2):239–245. doi: 10.1161/01.atv.17.2.239. [DOI] [PubMed] [Google Scholar]
  128. Williams J. K., Bellinger D. A., Nichols T. C., Griggs T. R., Bumol T. F., Fouts R. L., Clarkson T. B. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb. 1993 Apr;13(4):548–554. doi: 10.1161/01.atv.13.4.548. [DOI] [PubMed] [Google Scholar]
  129. Wissler R. W., Vesselinovitch D. Atherosclerosis in nonhuman primates. Adv Vet Sci Comp Med. 1977;21:351–420. [PubMed] [Google Scholar]
  130. Wright L. C., Sullivan D. R., Muller M., Dyne M., Tattersall M. H., Mountford C. E. Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer. 1989 Feb 15;43(2):241–244. doi: 10.1002/ijc.2910430212. [DOI] [PubMed] [Google Scholar]
  131. Zamboni M., Facchinetti R., Armellini F., Turcato E., Bergamo Andreis I. A., Bosello O. Effects of visceral fat and weight loss on lipoprotein(a) concentration in subjects with obesity. Obes Res. 1997 Jul;5(4):332–337. doi: 10.1002/j.1550-8528.1997.tb00560.x. [DOI] [PubMed] [Google Scholar]
  132. de Rijke Y. B., Jürgens G., Hessels E. M., Hermann A., van Berkel T. J. In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. J Lipid Res. 1992 Sep;33(9):1315–1325. [PubMed] [Google Scholar]
  133. van Kooten F., van Krimpen J., Dippel D. W., Hoogerbrugge N., Koudstaal P. J. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke. 1996 Jul;27(7):1231–1235. doi: 10.1161/01.str.27.7.1231. [DOI] [PubMed] [Google Scholar]
  134. van der Hoek Y. Y., Wittekoek M. E., Beisiegel U., Kastelein J. J., Koschinsky M. L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet. 1993 Apr;2(4):361–366. doi: 10.1093/hmg/2.4.361. [DOI] [PubMed] [Google Scholar]
  135. van der Mooren M. J., Mijatovic V., van Baal W. M., Stehouwer C. D. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas. 1998 Sep 20;30(1):27–36. doi: 10.1016/s0378-5122(98)00056-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES